Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia

2018 ◽  
Vol 59 (5) ◽  
pp. 668-676 ◽  
Author(s):  
Wangda Zhou ◽  
Dolly A. Parasrampuria ◽  
Sepideh Nemat ◽  
Susumu Nakahara ◽  
Italo Poggesi ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Pediatric Patients ◽  
Population Pharmacokinetic Analysis ◽  
Pharmacokinetic Analysis ◽  
Population Pharmacokinetic ◽  
Acute Myeloid

scholarly journals Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

2004 ◽  
Vol 22 (6) ◽  
pp. 1078-1086 ◽  
Author(s):  
Peter L. Greenberg ◽  
Sandra J. Lee ◽  
Ranjana Advani ◽  
Martin S. Tallman ◽  
Branimir I. Sikic ◽  
...  
Keyword(s):  
Overall Survival ◽  
Acute Myeloid Leukemia ◽  
High Risk ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Phase Iii ◽  
Pharmacokinetic Analysis ◽  
Population Pharmacokinetic ◽  
Poor Risk ◽  
Acute Myeloid

Purpose To determine whether adding the multidrug resistance gene-1 (MDR-1) modulator valspodar (PSC 833; Novartis Pharmaceuticals, Hanover, NJ) to chemotherapy provided clinical benefit to patients with poor-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Patients and Methods A phase III randomized study was performed using valspodar plus mitoxantrone, etoposide, and cytarabine (PSC-MEC; n = 66) versus MEC (n = 63) to treat patients with relapsed or refractory AML and high-risk MDS. Results For the PSC-MEC versus MEC arms, complete response (CR) was achieved in 17% versus 25% of patients, respectively (P = not significant). For patients who had not received prior intensive chemotherapy (ie, with secondary AML or high-risk MDS), the CR rate was increased—35% versus 15% for the remaining patients (P = .018); CR rates did not differ between treatment arms. The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients’ overall survival (4.6 versus 5.4 months). The CR rates in MDR+ (69% of patients) versus MDR− patients were similar for those receiving either chemotherapy regimen (16% versus 24%). The CR rate for unfavorable cytogenetic patients (45% of patients) was 13% compared to the remainder, 28% (P = .09). Population pharmacokinetic analysis demonstrated that the clearances of mitoxantrone and etoposide were decreased by 59% and 50%, respectively, supporting the empiric dose reductions in the PSC-MEC arm designed in anticipation of drug interactions between valspodar and the chemotherapeutic agents. Conclusion CR rates and overall survival were not improved by using PSC-MEC compared to MEC chemotherapy alone in patients with poor-risk AML or high-risk MDS.

scholarly journals Treatment adherence and abandonment in acute myeloid leukemia in pediatric patients at a low-resource cancer center in India

2019 ◽  
Vol 40 (4) ◽  
pp. 501
Author(s):  
Mikael Segerlantz ◽  
Sudha Sinha ◽  
Gustav Brattström ◽  
Gayatri Palat ◽  
Vineela Rapelli ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Treatment Adherence ◽  
Myeloid Leukemia ◽  
Pediatric Patients ◽  
Cancer Center ◽  
Low Resource ◽  
Acute Myeloid

scholarly journals Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0192529 ◽  
Author(s):  
Kelly D. Getz ◽  
Tamara P. Miller ◽  
Alix E. Seif ◽  
Yimei Li ◽  
Yuan-Shung V. Huang ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Pediatric Patients ◽  
Newly Diagnosed ◽  
Acute Myeloid

Cup-like Blasts in 2 Pediatric Patients With NPM-1-Positive Acute Myeloid Leukemia

2018 ◽  
Vol 40 (4) ◽  
pp. e237-e238
Author(s):  
Özlem Tüfekçi ◽  
Melek Erdem ◽  
Hale Ören ◽  
Şebnem Yilmaz
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Pediatric Patients ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document